Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
Irati Macaya(Universidad de Navarra), Silvestre Vicent(Navarre Institute of Health Research)
Cited by 23
Related Papers
An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer
|Nature Communications|2017|194
The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas
|Journal of Clinical Investigation|2019|50